India, Aug. 13 -- Abeona Therapeutics Inc. (ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies, reported financial results for the second quarter reflecting a swing to a net loss compared to profit a year ago, with the year-ago results largely driven by the sale of a priority review voucher.
Abeona's FDA-approved ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).
The company's development portfolio also includes ABO-701, an engineered T-cell therapy for solid tumours.
For the second quarter of 2026, the firm incurred a net loss of $20.19 million or $0.35 per share...